All News

Ashlee Klevens Hayes is a pharmacist, a keynote speaker, a co-host on the Pharmacy Podcast Network with her show Rx Buzz, and an entrepreneur with her business Rx Ashlee.

Darolutamide is an androgen receptor inhibitor (ARi) for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Abemaciclib (Verzenio, Eli Lilly) in combination with fulvestrant demonstrated a statistically significant improvement in overall survival among women with metastatic breast cancer previously treated with endocrine therapy.

Top news of the day from across the health care landscape.

The American Society of Health-System Pharmacists (ASHP) has released a statement opposing the Centers for Medicare and Medicaid Services’ (CMS) proposed cuts to reimbursement for drug purchased through the 340B Drug Pricing Program.

Vaccine found to provide durable protection against the “death star” HIV strain, which is notably hard to fight.

Darolutamide, an androgen receptor inhibitor (ARi) for the treatment of patients with non-metastatic castration-resistant prostate cancer, was approved by the FDA this week.

The new product is available in the United States in 20- and 30-count sizes.

Researchers aimed to determine the potential pathology of encephalitis as a complication of immunotherapy treatment.

Top news of the day from across the health care landscape.

The MJH SAP program partners Hematology-Oncology Associates of Central New York with Targeted Oncology™, The American Journal of Managed Care® and Pharmacy Times®,

Mylan and Pfizer have announced an agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business.

Data from a pair of phase 3 trials were recently presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City.

Erdafitinib (Balversa, Janssen) is the first FGFR inhibitor to receive FDA approval for the treatment of patients with metastatic bladder cancer marked by FGFR gene mutations.

Why is this healthy young man getting severe brain fog?

Top news of the day from across the health care landscape.

Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.

In a study by Johns Hopkins Medicine, investigators used an advanced form of brain scan to demonstrate that 12 participants in their study with documented posttreatment Lyme disease syndrom (PTLDS) all showed elevation of a chemical marker of wide-spread brain inflammation compared with 19 controls.

Results from an ongoing safety trial of tofacitinib demonstrated an increased risk of blood clots and death associated with a 10-mg twice daily dose of tofacitinib in patients with rheumatoid arthritis.

Top news of the day from across the health care landscape.

Investigators find that radiation equivalent to 3 CT scans prompts the growth of the p53 mutation in mice.

Top news of the week from Specialty Pharmacy Times.

A recent study found the prevalence of COPD was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.

The FDA has granted Eli Lilly and Company approval for its nasal powder glucagon (Baqsimi) for emergency treatment of severe hypoglycemia.

If approved, tazemetostat, a first-in-class EZH2 inhibitor, would be indicated for the treatment of metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

More colorectal cancer cases are being diagnosed in adults under the age of 50, with younger adults presenting with more advanced disease than those older than 50 years.

Long-term use of ivacaftor and other drugs that correct detects in the cystic fibrosis gene could potentially prevent chronic infections from developing.

Top news of the day from across the health care landscape.

A species of deer parasites known as deer keds, or Lipoptena cervi, is more widely distributed across the United States than previously thought, according to Pennsylvania State University entomologists, who noted the parasites' potential to transmit disease-causing bacteria.

A coalition of health ministries, investigators, and the World Health Organization (WHO) has outlined the key steps to develop a global program to control scabies, a parasitic disease that affects 450 million people each year in mainly low-income countries.